TrialClinical pharmacokinetics2017

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group.

Mira Tout et al.PubMed ↗Publisher ↗

No numbers read from the abstract.